Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance

Abstract

Fractalkine has been reported to play an important role in the pathophysiology of various cardiovascular disorders. This research aims to study the change of soluble fractalkine (sFKN) in plasma level of patients with chronic heart failure (CHF) and evaluate its prognostic value. A total of 96 patients with CHF and 45 healthy subjects were included in this study. The plasma levels of sFKN, brain natriuretic peptide (BNP), and Interleukin-18 (IL-18) were determined by ELISA kits when they were first admitted to the hospital. Left ventricular ejection fraction (LVEF) was measured by echocardiogram. Rehospitalization status within 1 year after the first hospitalization was also recorded. The plasma levels of sFKN, BNP, and IL-18 in patients with CHF were significantly higher than in the control group (P < 0.05). The concentrations of sFKN and BNP were increased with the severity of heart failure classified by NYHA classification (P < 0.05). There were no statistical differences among all CHF subgroups classified by etiology (P > 0.05). Plasma sFKN level in CHF group was positively correlated with BNP (r = 0.441, P < 0.001) and IL-18 (r = 0.592, P < 0.001). Receiver operating characteristic curve analysis showed that area under the curve values of FKN, BNP, and IL-18 were 0.885 (95%CI: 0.810 to 0.960, P < 0.001), 0.889 (95%CI: 0.842 to 0.956, P < 0.001), and 0.878 (95%CI: 0.801-0.954, P < 0.001), respectively. The concentrations of sFKN and BNP were increased in patients readmitted more than once within 1 year (P < 0.05).

Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?

“…Additionally, serum CX3CL1 concentration been shown to be predictive of all-cause mortality and myocardial infarction in CKD cohorts (80,81). Such observations have also been made in non-CKD populations (82,83). Expression of CX3CR1 by circulating leukocytes may also be altered in CKD or ESKF.…”

The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure

“…ith the rise in the aging population, morbidity and mortality from chronic heart failure (CHF) presents an increasing trend, and with a five-year survival rate around 50%, it is a serious threat to human health. 1,2) CHF is the terminal stage of most myocardial diseases. Such a condition results from various forms of cardiomyocyte injury, and it changes the structure of the cardiomyocyte, resulting in cardiac remodeling and eventually depresses the heart's blood pumping func-tion.…”

Interleukin-18 and cardiovascular diseases: a literature review

“…ROC-анализ показал, что площадь под кривыми sFKN, BNP и IL-18 составила 0,885 (95% ДИ 0,810-0,960; p <0,001), 0,889 (95% ДИ 0,842-0,956; p <0,001) и 0,878 (95% ДИ 0,801-0,954; p <0,001) соответственно. Концентрации изучаемых маркёров были повышены у пациентов, повторно госпитализированных более 1 раза в течение 1 года (p <0,05) [45].…”